Tempus AI (TEM) is back in focus after publishing a multi site validation of its FDA cleared ECG AF software, which predicts one year atrial fibrillation or flutter risk in older adults without prior AF.

Tempus AI’s shares have picked up momentum recently, with a 1 month share price return of 10.81% and a 7 day gain of 6.32%. However, the year to date share price return is still down 18.47% and the 1 year total shareholder return has declined 25.57%. This suggests investors are reassessing the stock as fresh product milestones like the ECG AF validation and recent conference appearances reset expectations.

If today’s move has you looking at the wider opportunity in healthcare AI, it can be helpful to scan other specialists using the 41 healthcare AI stocks.

With Tempus AI’s shares rebounding over the past month yet still down sharply over the year, and trading at a discount to analyst price targets and some intrinsic estimates, investors may be asking whether there is still an opportunity at current levels or whether the market has already priced in future growth.

Most Popular Narrative: 22.9% Undervalued

Tempus AI’s most followed narrative points to a fair value of $65.90 per share versus the last close at $50.84. That story-driven estimate is meaningfully higher than where the stock currently trades.

This data moat is what makes the business interesting.

Tempus has accumulated tens of millions of de-identified patient records and hundreds of petabytes of clinical and molecular data, assets that would take competitors years and enormous investment to replicate.

Read the complete narrative. Read the complete narrative.

The fair value hinges on Tempus AI compounding its data advantage into stronger margins and recurring revenue, while applying a future profit multiple more typical of leading software platforms. Curious which growth, margin, and valuation assumptions have the biggest impact on that $65.90 outcome.

According to QuanD, the narrative leans heavily on Tempus AI’s position as a healthcare data platform, where diagnostics, clinical data, and AI tools feed a single ecosystem. It also assumes that higher margin data and software revenue becomes a larger slice of the mix over time, and that the market eventually prices the company closer to established software platforms rather than a pure diagnostics provider.

Result: Fair Value of $65.90 (UNDERVALUED)

However, Tempus AI’s story still faces pressure from ongoing losses of $302.91 million and the risk that AI healthcare adoption or data licensing ramps more slowly than hoped.

Another View on Tempus AI’s Valuation

While the leading Tempus AI narrative leans on future revenue and profit multiples, the current P/S of 6.7x tells a more cautious story. That level is much higher than both the US Life Sciences industry and peer average of 3.8x, yet sits below a fair ratio of 7.2x.

In practice, that means the stock already trades at a premium to many comparable companies, even if there is still some room before it reaches the fair ratio level the market could move toward over time. The question for investors is which signal to weigh more heavily right now.

Next Steps

Seeing mixed signals around Tempus AI’s valuation and outlook. If you want to move quickly and shape your own view, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Tempus AI?

If Tempus AI has sharpened your interest in focused stock picking, do not stop here. Broaden your watchlist with a few targeted screens built for different goals.

• Hunt for underappreciated quality by scanning companies trading below their estimated worth using the 45 high quality undervalued stocks.
• Prioritize resilience by filtering for businesses that pair financial strength with consistent fundamentals through the solid balance sheet and fundamentals stocks screener (48 results).
• Spot income-focused opportunities by targeting companies with robust payouts using the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.